BIOMERICA INC
Form 8-K
January 10, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 13, 2017**

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware	**0-8765**	**95-2645573**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

17571 Von Karman Ave. Irvine, California	**92614**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(949) 645-2111**

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote of Security Holders.

Biomerica, Inc. (the Company) held its 2017 annual meeting (the 2017 Annual Meeting) of stockholders of the Company on December 13, 2017 in Irvine, California. As of October 20, 2017, the record date for the 2017 Annual Meeting, the Company had 8,515,173 shares of its common stock outstanding and entitled to vote, of which 7,146,419 shares of the Company s common stock were present in person or represented by proxy and entitled to vote at the 2017 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2017 Annual Meeting.

Proposal No. 1: The Company s stockholders elected each of the six nominees named below to serve on the Company s Board of Directors until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.

Nominee	Votes For	Votes Withheld	Broker Non-votes
Zackary Irani	4,043,904	11,556	3,499,545
Janet Moore	4,036,105	19,355	3,499,545
Allen Barbieri	4,037,054	18,406	3,499,545
Francis R. Cano, Ph.D.	3,832,733	222,727	3,499,545
Jane Emerson, M.D., Ph.D.	4,043,954	11,506	3,499,545
Mark Sirgo, Pharm. D.	3,995,397	60,063	3,499,545

Proposal No. 2: The Company s stockholders approved the Company s 2017 Stock Incentive Plan.

Votes For	Votes Against	Votes Abstaining	Broker Non-Votes
3,373,824	533,117	13,519	3,499,545

Proposal No. 3: The Company s stockholders ratified the appointment of PFK, LLP as the Company s independent public accounting firm for the fiscal year ending May 31, 2018.

Votes For	Votes Against	Votes Abstaining	Broker Non-Votes
6,998,392	110,557	37,470	---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOMERICA, INC.

Date: January 10, 2018	By:	/s/ Zackary S. Irani Zackary S. Irani Chief Executive Officer